Efficacy and Safety of Rivaroxaban Compared with Warfarin among Elderly Patients with Nonvalvular Atrial Fibrillation in the ROCKET AF Trial
Clinical Trials Saturday, July 5th, 2014CIRCULATIONAHA: June 3, 2014
Background—Nonvalvular atrial fibrillation (AF) is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the ROCKET AF trial. This prespecified secondary analysis compares outcomes in older and younger patients.
Methods and Results—There were 6229 patients (44%) aged ≥75 years with AF and ≥2 stroke risk factors randomized to warfarin (target international normalized ratio 2.0-3.0) or rivaroxaban (20 mg daily; 15 mg if creatinine clearance <50 mL/min), double-blind. The primary endpoint was stroke and systemic embolism (SE) by intention-to-treat (ITT). Read More
